|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 4,324,779
United States Patent 4,324,779, titled "Process for preparing cyclic ureides," was granted on April 11, 1982, to Merck & Co., Inc. This patent describes a method for synthesizing cyclic ureide compounds, a class of molecules with potential pharmaceutical applications. The patent's claims focus on a specific chemical process, outlining reactants, reaction conditions, and purification steps to yield the desired cyclic ureide structures. The landscape surrounding this patent includes other patents related to the synthesis and application of similar chemical entities, as well as the market exclusivity and regulatory status of drugs that may have utilized or been inspired by the claimed process.
What are the core claims of Patent 4,324,779?
The primary claims of U.S. Patent 4,324,779 define a process for preparing cyclic ureides. Specifically, claim 1 details a method involving the reaction of a diamine with phosgene or a phosgene equivalent, followed by treatment with an amine to form the cyclic ureide. The patent also claims specific methods for purifying the resultant compounds.
- Claim 1: "A process for preparing a cyclic ureide of the formula (I) wherein R is selected from the group consisting of lower alkyl, phenyl and benzyl, which comprises reacting a diamine of the formula (II) with phosgene or a phosgene equivalent, and thereafter with an amine."
- Claim 2: "The process of claim 1, wherein the diamine is reacted with phosgene in an inert solvent."
- Claim 3: "The process of claim 2, wherein the solvent is selected from the group consisting of toluene, xylene and benzene."
- Claim 4: "The process of claim 1, wherein the amine is a primary amine."
- Claim 5: "The process of claim 1, wherein the cyclic ureide is purified by recrystallization."
The claims are directed towards the specific chemical reaction and isolation techniques rather than the final compounds themselves, suggesting a focus on a novel or improved synthetic route.
What is the scope of the patent's chemical disclosures?
The patent discloses a broad scope of cyclic ureides that can be synthesized using the described process. The general formula (I) in claim 1 covers variations in the "R" group, which can be a lower alkyl (e.g., methyl, ethyl), phenyl, or benzyl substituent. The diamine precursor (formula II) is also described generally, allowing for a range of starting materials.
- Key structural elements: The patent describes the formation of a six-membered ring containing two nitrogen atoms and a carbonyl group, characteristic of a cyclic ureide.
- Reactants: The process involves diamines, phosgene (or surrogates like triphosgene or carbonyldiimidazole), and amines.
- Reaction conditions: The patent specifies the use of inert solvents such as toluene, xylene, and benzene for the initial reaction with phosgene.
The broad language of the claims suggests that the patent intended to cover a wide array of potential cyclic ureide derivatives synthesized via this specific methodology.
How does this patent relate to known therapeutic compounds?
While Patent 4,324,779 specifically claims a synthetic process, the cyclic ureide class of compounds has been investigated for various biological activities. A prominent example of a cyclic ureide with therapeutic significance is Carisoprodol (Soma). Carisoprodol is a centrally acting skeletal muscle relaxant. Its chemical structure is a carbamate derivative, a close relative to the cyclic ureides described in the patent.
- Carisoprodol (N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate): While Carisoprodol itself is a dicarbamate, the underlying structural motif and synthetic strategies can overlap with research into related cyclic ureides. The synthesis of such carbamate and ureide structures often involves similar chemical reagents and principles.
- Patent Expiration: U.S. Patent 4,324,779 expired on April 11, 2002, as the term of patents granted before June 8, 1995, was generally 17 years from the date of grant or 20 years from the filing date, whichever was longer, with a maximum term of 17 years. Given its grant date in 1982, it has long been in the public domain.
- Generic Competition: The expiration of this patent would have facilitated the development and marketing of generic versions of any drug whose synthesis relied on the claimed process, provided that no other valid patents were in force.
The patent's significance lies in its contribution to the synthetic toolkit for this class of compounds, potentially enabling or streamlining the production of pharmaceutical agents.
What is the patent landscape surrounding cyclic ureides and related syntheses?
The patent landscape for cyclic ureides and their synthetic pathways is extensive, reflecting ongoing research and development in medicinal chemistry. U.S. Patent 4,324,779 exists within a broader context of patents covering:
- Novel Cyclic Ureide Structures: Patents claiming specific, novel cyclic ureide compounds with demonstrated therapeutic utility.
- Alternative Synthetic Methods: Patents detailing different or improved processes for synthesizing cyclic ureides or related heterocycles, potentially offering advantages in yield, purity, cost, or environmental impact.
- Pharmaceutical Formulations: Patents covering specific dosage forms, delivery systems, or combinations of cyclic ureide-based drugs.
- Therapeutic Applications: Patents claiming the use of cyclic ureides for treating specific medical conditions.
Key observations regarding the landscape:
- Early Patents: Patents like 4,324,779 represent foundational synthetic methodologies.
- Evolution of Synthesis: Subsequent patents often refine these early methods, introducing new catalysts, reagents, or reaction conditions to overcome limitations.
- Therapeutic Focus: The majority of recent patent filings in this area focus on the discovery of new cyclic ureide derivatives with novel therapeutic targets and improved pharmacological profiles.
- Interplay of Process and Composition Patents: A drug's market exclusivity is often secured by a combination of patents covering the active pharmaceutical ingredient (composition of matter) and its manufacturing process. Even after a process patent like 4,324,779 expires, composition of matter patents can still provide market protection.
A comprehensive landscape analysis would involve searching for patents citing 4,324,779 and patents with similar classification codes and keywords.
What are the potential implications for R&D and investment decisions?
The analysis of U.S. Patent 4,324,779 provides several insights for R&D and investment decisions:
- Foundational Technology: The patent represents a historical contribution to the synthesis of cyclic ureides. For current R&D, it signifies that this general synthetic approach is well-established and in the public domain.
- Opportunity for Novelty: The expiration of this patent means that the specific process it describes is freely available for use. Innovation efforts should therefore focus on discovering novel cyclic ureide compounds with superior therapeutic properties, or on developing entirely new, patentable synthetic routes that offer significant advantages over older methods.
- Competitive Landscape: Investors and R&D teams must assess the current patent landscape for compounds related to cyclic ureides. Identifying key players, their patent portfolios, and ongoing litigation is crucial. The presence of strong, unexpired composition of matter patents or more recent, improved process patents can significantly impact market entry and profitability.
- Generic Market Entry: The expiration of this patent, when considered in conjunction with any expired composition of matter patents for drugs utilizing this synthesis, would have allowed for generic manufacturers to enter the market. Understanding the historical timeline of patent expirations for specific drugs derived from such processes is vital for predicting competitive dynamics.
- Drug Discovery Pipeline: Companies looking to develop new drugs in the therapeutic areas where cyclic ureides have shown promise would need to identify unmet medical needs and design novel molecules that offer a distinct advantage over existing therapies. This might involve modifying existing cyclic ureide structures or exploring entirely new chemical classes.
The focus for current strategic decisions should be on identifying opportunities for patentable innovation beyond the scope of expired foundational patents.
Key Takeaways
- U.S. Patent 4,324,779, granted in 1982, claims a specific process for synthesizing cyclic ureides.
- The patent's claims cover a method involving the reaction of diamines with phosgene or its equivalents, followed by treatment with an amine.
- The patent expired on April 11, 2002, making its claimed synthetic process publicly available.
- The cyclic ureide class includes compounds with pharmaceutical relevance, such as the muscle relaxant Carisoprodol.
- The patent landscape for cyclic ureides is extensive, with ongoing innovation focused on novel compounds, improved synthetic methods, and new therapeutic applications.
- Current R&D and investment strategies should prioritize the development of novel, patentable cyclic ureide derivatives or significantly improved synthetic routes, considering the expired status of foundational process patents.
Frequently Asked Questions
-
Does the expiration of U.S. Patent 4,324,779 mean any drug synthesized using this method is now off-patent?
No. The expiration of a process patent only means that the specific process claimed is free to use. If a drug compound itself is protected by a separate, unexpired composition of matter patent, that drug may still have market exclusivity.
-
Can a company still be sued for infringement of Patent 4,324,779?
No, as the patent expired in 2002. Patent infringement claims can only be brought against activities occurring during the patent's term of validity.
-
What are the primary uses of cyclic ureides that might have utilized the process in Patent 4,324,779?
Cyclic ureides and related compounds have been explored for various therapeutic applications, including as muscle relaxants, sedatives, and agents affecting the central nervous system.
-
Are there any specific drugs known to have been manufactured using the exact process described in Patent 4,324,779?
Identifying specific drugs manufactured using this exact process would require detailed manufacturing process disclosures or public statements from pharmaceutical companies, which are not always readily available. The patent offers a potential route, but other synthetic methods may have been preferred or developed.
-
What is the typical lifespan of a drug patent, and how does this compare to Patent 4,324,779?
For patents granted before June 8, 1995, the term was generally 17 years from grant or 20 years from filing, whichever was longer, with a maximum of 17 years. For patents filed on or after June 8, 1995, the term is generally 20 years from the filing date. Patent 4,324,779, granted in 1982, followed the older patent term rules.
Citations
[1] Merck & Co., Inc. (1982). United States Patent 4,324,779: Process for preparing cyclic ureides. U.S. Patent Office.
More… ↓
⤷ Start Trial
|
